Acrivon's ACR-368 shows 35% cORR in endometrial cancer; cash $164.8M

Acrivon Therapeutics, Inc.

2025-Q1 EPS reported -$0.51

Q1 2025 net loss $19.7M vs $16.5M YoY; R&D spend $15.4M on trial advancement.
Cash, equivalents and securities $164.8M; runway into Q2 2027.
ACR-368 Phase 2b: 35% cORR, 80% DCR in OncoSignature+ patients; 50% cORR in relapsed subset.
ACR-2316 Phase 1: DL4 enrolling; ~25% tumor shrinkage at DL3 below projected RP2D.
Appointed Mansoor Raza Mirza as CMO; promoted Adam Levy to CFO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.